MedTrace Logo

Neo-adjuvant Abiraterone Prostate Study

NCT02160353 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-04-13

No results posted yet for this study

Summary

The role of this study is to focus on the potential role of abiraterone acetate in treatment-naive patients newly diagnosed with high-risk localised prostate cancer requiring combined hormonal therapy and radiotherapy.

Conditions

  • High Risk Localised Prostate Carcinoma

Interventions

DRUG

Abiraterone acetate, Prednisolone

Sponsors & Collaborators

  • Janssen, LP

    collaborator INDUSTRY

  • Cancer Trials Ireland

    lead NETWORK

Principal Investigators

  • Pierre Thirion, Dr · St Luke's Radiation Oncology Network, St Luke's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-09
Primary Completion
2021-01-19
Completion
2021-01-19

Countries

  • Ireland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02160353 on ClinicalTrials.gov